Normo~CAT: Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites

Sponsor
Sanofi (Industry)
Overall Status
Completed
CT.gov ID
NCT00501566
Collaborator
(none)
148
12
9
12.3
1.4

Study Details

Study Description

Brief Summary

The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide.

The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites.

Condition or Disease Intervention/Treatment Phase
  • Drug: satavaptan (SR121463B)
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
148 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
SR121463B in Cirrhotic Ascites Treatment With Normonatraemia: A Placebo-Controlled, Dose-Comparison Study
Study Start Date :
Apr 1, 2004
Actual Study Completion Date :
Jan 1, 2005

Outcome Measures

Primary Outcome Measures

  1. Change in body weight [within 14 days]

Secondary Outcome Measures

  1. Abdominal girth and discomfort [14 days]

  2. Paracentesis [14 days]

  3. Quality of life [14 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Cirrhosis of the liver confirmed by ultrasound, endoscopic examination or biochemical evidence

  • Moderate or tense ascites

  • Serum sodium of >130 mmol/l.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sanofi-Aventis Administrative Office Buenos Aires Argentina
2 Sanofi-Aventis Administrative Office Cove New South Wales Australia
3 Sanofi-Aventis Administrative Office Diegem Belgium
4 Sanofi-Aventis Administrative Office Laval Quebec Canada
5 Sanofi-Aventis Administrative Office Zagreb Croatia
6 Sanofi-Aventis Administrative Office Praha Czech Republic
7 Sanofi-Aventis Administrative Office Paris France
8 Sanofi-Aventis Administrative Office Berlin Germany
9 Sanofi-Aventis Administrative Office Budapest Hungary
10 Sanofi-Aventis Administrative Office Milan Italy
11 Sanofi-Aventis Administrative Office Bucuresti Romania
12 Sanofi-Aventis Administrative Office Barcelona Spain

Sponsors and Collaborators

  • Sanofi

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00501566
Other Study ID Numbers:
  • DFI5563
  • SR121463
First Posted:
Jul 16, 2007
Last Update Posted:
Jul 16, 2007
Last Verified:
Jul 1, 2007
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2007